30 mayo 2015
A new phase 3 study in some of the most difficult-to-treat patients, women with endocrine-resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone-receptor (HR+) positive metastatic breast cancer.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/gPh1JyzElSo/150530102214.htm
